OncLive TV

Alexander Olawaiye, MD, discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

Manish Patel, DO, discusses future directions for investigating hormonal plus immune therapies for the treatment of patients with salivary gland cancer.

Manish Patel, DO, discusses AEs seen with ADT plus pembrolizumab in patients with advanced-stage, androgen receptor–positive salivary gland cancer.

Sun Yang, MD, discusses the activity of frontline cadonilimab plus chemotherapy in patients with recurrent/advanced endometrial carcinoma.

Bhavana Pothuri, MD, discusses phase 2 data with trastuzumab pamirtecan (DB-1303/BNT323) in pretreated patients with HER2-expressing endometrial cancer.

Rana R. McKay, MD, discusses findings from the phase 4 OPTYX trial of real-world relugolix in advanced prostate cancer.

Manish Patel, DO, discusses response rates seen with ADT in combination with pembrolizumab in advanced, androgen receptor–positive salivary gland cancer.

Rana R. McKay, MD, discusses, the study design and baseline patient characteristics of the OPTYX trial of relugolix in advanced prostate cancer

Tara Graff, DO, details the role of CAR T-cell therapy in the relapsed/refractory diffuse large B-cell lymphoma treatment paradigm.

Lipika Goyal, MD, contextualizes the safety profile of lirafugratinib with that of other FGFR inhibitors in FGFR2-altered cholangiocarcinoma.

Richard F. Riedel, MD, discusses the diagnosis of PEComa and referral/treatment planning following diagnosis.

Manish Patel, DO, discussed the single-arm BTCRC HN17-111 study investigating ADT plus pembrolizumab in advanced, AR-positive salivary gland cancer.

Rana R. McKay, MD, discussed the rationale behind the phase 4 OPTYX trial evaluating relugolix in advanced prostate cancer.

Lore Gruenbaum, PhD, discusses the FDA approval of brexu-cel for mantle cell lymphoma and its significance for the treatment paradigm.

Lipika Goyal, MD, discusses results from the phase 1/2 ReFocus trial shared during the 2026 Gastrointestinal Cancers Symposium.

Wade Iams, MD, MSCI, discusses the management of LEMS in the context of SCLC.

Manish Patel, DO, discussed the unmet needs that led to the investigation of ADT plus pembrolizumab in patients with advanced salivary gland carcinoma.

Lipika Goyal, MD, discusses the highly selective, irreversible mechanism of lirafugratinib and its potential to overcome resistance in FGFR2-altered CCA.

Ticiana Leal, MD, discusses screening for LEMS in patients with SCLC.

Jennifer R. Brown, MD, PhD, discusses the design of the AMPLIFY trial and safety data for acalabrutinib plus venetoclax in chronic lymphocytic leukemia.

Christopher Lieu, MD, discusses the need for global collaboration and interdisciplinary research to address the rise of early-onset CRC.

Jennifer R. Brown, MD, PhD, discusses ongoing clinical trials that she has her eye out for in chronic lymphocytic leukemia.

John L. Marshall, MD, discusses how the clinical reality of early-onset CRC in young, fit patients contradicts traditional lifestyle-based assumptions.

Akshit Chitkara, MD, discusses outcomes with IO doublet therapy by dedifferentiation status and histologic grade in ccRCC.

Jeffrey Zhong, MD, discusses the effect of upfront enfortumab vedotin/pembrolizumab dose reduction on treatment efficacy in advanced urothelial carcinoma.

Quinto Gesiotto, MD, discusses optimal dosing strategies for ponatinib in the treatment of chronic-phase chronic myeloid leukemia.

Amrita Krishnan, MD, shares the significance of the FDA approval of daratumumab plus teclistamab in relapsed/refractory multiple myeloma.

Jennifer R. Brown, MD, PhD, discusses the FDA approval of acalabrutinb and venetoclax for chronic lymphocytic leukemia and its effect on patient QOL.

Christopher R. D’Angelo, MD, discusses the BTK inhibitors and their role in primary central nervous system lymphoma.

Mazyar Shadman, MD, MPH, discusses a post hoc analysis that compared data BTK inhibitor–based regimens for treatment-naive chronic lymphocytic leukemia.